Icosavax, Inc. announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research and development, including at two of the most prominent vaccine companies in the world, Sanofi Pasteur and Merck & Co., Inc. He has guided scientific teams to create novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including RSV, influenza, pneumococcus, CMV, HIV, HPV, cancer, and asthma, and contributed to the licensure of 14 products. Currently, Dr. Shiver is Chief Strategy Officer, leader of the scientific advisory board, and member of the Board of Directors at IGM ID, a wholly owned subsidiary of IGM Biosciences.